Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Authors

Tjalf Ziemssen, Technische Universität Dresden
Ann D. Bass, Neurology Center of San Antonio
Regina Berkovich, PhD, Inc.
Giancarlo Comi, Vita-Salute San Raffaele University
Sara Eichau, Hospital Universitario Virgen Macarena
Jeremy Hobart, Peninsula Medical School
Samuel F. Hunter, Advanced Neurosciences Institute
Christopher LaGanke, North Central Neurology Associates
Volker Limmroth, Klinik für Neurologie und Palliativmedizin
Daniel Pelletier, University of Southern California
Carlo Pozzilli, University of Rome La Sapienza
Sven Schippling, University of Zurich
Livia Sousa, University of Coimbra
Anthony Traboulsee, University of British Columbia
Bernard M.J. Uitdehaag, Amsterdam University Medical Centers
Wijmeersch B Van
Zia Choudhry, Sanofi
Nadia Daizadeh, Sanofi
Barry A. Singer, Washington University St. Louis

ORCID

• Jeremy Hobart: 0000-0002-2114-7920

DOI

10.1007/s40263-020-00749-x

Publication Date

2020-07-24

Publication Title

CNS Drugs

ISSN

1172-7047

Embargo Period

2020-08-11

Recommended Citation

Ziemssen, T., Bass, A., Berkovich, R., Comi, G., Eichau, S., Hobart, J., Hunter, S., LaGanke, C., Limmroth, V., Pelletier, D., Pozzilli, C., Schippling, S., Sousa, L., Traboulsee, A., Uitdehaag, B., Van, W., Choudhry, Z., Daizadeh, N., & Singer, B. (2020) 'Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study', CNS Drugs, . Available at: 10.1007/s40263-020-00749-x